Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases

V. A. Trivillin, M. A. Garabalino, L. L. Colombo, S. J. González, R. O. Farías, A. Monti Hughes, E. C.C. Pozzi, S. Bortolussi, S. Altieri, M. E. Itoiz, R. F. Aromando, D. W. Nigg, A. E. Schwint

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25-76. ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.

Original languageEnglish
Pages (from-to)94-98
Number of pages5
JournalApplied Radiation and Isotopes
Volume88
DOIs
Publication statusPublished - Jun 2014
Externally publishedYes

Keywords

  • BNCT
  • Boron biodistribution studies
  • Boron Neutron Capture Therapy
  • BPA
  • GB-10
  • Lung metastases

ASJC Scopus subject areas

  • Radiation

Fingerprint

Dive into the research topics of 'Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases'. Together they form a unique fingerprint.

Cite this